CME in Minutes: Education in Oncology & Hematology

Please visit answersincme.com/TNM860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Richard Kim, MD. In this activity, an expert in oncology discusses when and how to sequence later-line and chemotherapy-free therapies in metastatic colorectal cancer (mCRC). Upon completion of this activity, participants should be better able to: Evaluate factors influencing a treatment switch from cytotoxic agents for patients with stable metastatic colorectal cancer (mCRC); Formulate practical approaches for transitioning from chemotherapy to tyrosine kinase inhibitor (TKI) treatment in later-line settings for patients with mCRC; and Describe strategies to prolong chemotherapy-free disease control with TKIs.

Please visit answersincme.com/KJW860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Aman Chauhan, MD and Rhonda K. Yantiss, MD. In this activity, experts in medical oncology and pathology discuss identification and treatment of extrapulmonary neuroendocrine carcinomas and extrapulmonary neuroendocrine tumors. Upon completion of this activity, participants should be better able to: Differentiate extrapulmonary neuroendocrine carcinoma (EP-NEC) from extrapulmonary neuroendocrine tumors (EP-NETs); Identify diagnostic and pathological approaches to improve the recognition and accurate classification of EP-NEC and EP-NET; Evaluate emerging clinical data on DLL3-targeting bispecific TCE agents in the treatment of EP-NEC and EP-NET; and Formulate evidence-based strategies to integrate DLL3-targeting bispecific TCE therapies into evolving treatment paradigms for EP-NEC and EP-NET.

Please visit answersincme.com/DDT860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Robert Haddad, MD. In this activity, an expert in medical oncology discusses locally advanced head and neck squamous cell carcinoma (LA HNSCC). Upon completion of this activity, participants should be better able to: Discuss the clinical implications of the latest data for approved and recommended regimens for resectable LA HNSCC in the pre- and postoperative settings; Outline strategies to integrate immunotherapy into pre- and postoperative settings for resectable LA HNSCC, in the context of conventional treatment; and Apply multidisciplinary team approaches to effectively manage patients with LA HNSCC across pre- and postoperative treatment phases.

Please visit answersincme.com/860/103518989-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by John Strickler, MD and Tanios Bekaii-Saab, MD. In this activity, experts in metastatic colorectal cancer (mCRC) discuss proactive toxicity management and dose optimization strategies to help patients remain on treatment and improve outcomes. Upon completion of this activity, participants should be better able to: Integrate proactive management strategies to maintain patients on later-line therapy.

Please visit answersincme.com/860/103518989-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by John Strickler, MD; and Daniel Ahn, DO, MS. In this activity, experts in metastatic colorectal cancer (mCRC) discuss strategies for sequencing later-line therapies and planning treatment pathways to preserve future options. Upon completion of this series, participants should be better able to: Apply evidence-based strategies for later-line treatment selection in mCRC; Integrate proactive management strategies to maintain patients on later-line therapy; and Propose treatment plans based on predictors of durable benefit and real-world evidence.